Tesamorelin
GHRH analog · approved for HIV-associated lipodystrophy
Overview
Tesamorelin is a synthetic GHRH analog studied for visceral-fat reduction and GH-axis modulation. Available in multiple lyophilized vial sizes for compounding-pharmacy and research applications.
Specifications
- CAS
- 218949-48-5
- Appearance
- White lyophilized powder
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg, 10 mg, 20 mg
- MOQ
- On request
- Lead time
- 10–18 days
- Storage
- -20°C, protect from light
Documentation available on request
- Certificate of Analysis (COA)
- HPLC Chromatogram
- Mass-spec spectrum
- Stability data
- SDS / MSDS
- Sequence verification
Related peptides
Buyers who view Tesamorelin also ask about:
Sermorelin
GHRH 1-29 fragment
- CAS
- 86168-78-7
- Vial
- 2 mg–10 mg
MOQ on requestGet quote →
CJC-1295 (no DAC)
Modified GRF 1-29 · GHRH analog
- CAS
- (see DAC-version distinction)
- Vial
- 2 mg–10 mg
MOQ on requestGet quote →
Tesamorelin + Ipamorelin Blend (15 mg)
GH-axis blend (Tesamorelin + Ipamorelin) — 15 mg total
- CAS
- (blend — components have individual CAS numbers)
- Vial
- 15 mg
MOQ on requestGet quote →